SEC Form 4 · accession 0001209191-19-018084
Cue Biopharma, Inc. · CUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Colin Sandercock
Officer — SVP, General Counsel and Sec
Period of report
Mar 6, 2019
Accepted (ET)
Mar 8, 2019 · 4:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645460
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $6.42 | Mar 6, 2019 | A | 50,000 | A | — | Mar 6, 2029 | Common Stock | 50,000 | 50,000 | D |
| Stock Option (right to buy)F2 | $7.50 | Mar 6, 2019 | A | 100,000 | A | — | Dec 27, 2024 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019.
- F2Represents a stock option award granted on December 27, 2017 that partially vested upon the achievement of certain performance based conditions as determined by the Compensation Committee of Cue Biopharma, Inc. on March 6, 2019. As of March 6, 2019, 65,000 of these options were vested and exercisable. The remaining 35,000 will become vested and exercisable only upon the achievement of certain performance based conditions.